Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients

Carol A. Huseman, John Louis Colombo, Margaret A. Brooks, Jeanne R. Smay, Nancy G. Greger, Paul Henry Sammut, Dennis M. Bier

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The purpose of this study was to determine whether GH treatment of cystic fibrosis (CF) patients can result in an anabolic effect, i.e., increased weight gain, improved growth rate, nitrogen retention, and improved pulmonary function. Nine prepubertal endocrinologically normal CF patients (3 girls, 6 boys; chronological age (CA) 5.5-9.8 years, and bone age (BA) 4.5- 9.0 years), received recombinant human growth hormone (rhGH) 0.3 mg/kg/week subcutaneously for a period of 12 months (N = 8) or 9 months (N = 1). Normal glucose tolerance was determined before treatment. Pulmonary function studies and anthropometric measurements were done every 3 months. Thyroid status, somatomedin C (SmC), BA, and routine chemistries were evaluated every 6 months. The pretreatment growth velocity averaged 5.7 ± 0.3 (SE) cm/year and significantly increased to 7.8 ± 0.4 (SE) cm/year during therapy, (P < 0.01). Standard deviation scores (SDS) for height significantly increased during rhGH therapy as compared with pretreatment, (P < 0.05). Weight of the patients during rhGH therapy did not significantly change during or after rhGH therapy. After therapy, all patients showed a significant increase in arm muscle area (AMA) and a significant decrement in arm fat area (AFA) (P < 0.01). Net nitrogen anabolism was negative in all subjects before therapy but became more positive in five patients during rhGH therapy. Three patients achieved positive nitrogen retention. SmC values significantly increased from a mean value of 0.62 ± 0.1 (SE) U/ml to 1.6 ± 0.6 (SE) U/ml after therapy. BA advanced 1.0 ± 0.1 SE per year after treatment. Of the seven patients able to perform adequate pulmonary function testing, improvement occurred in FVC, FEV(10 t), and PEFR in 5, 5, and 4 patients, respectively, but these changes did not reach statistical significance. We conclude that biosynthetic rhGH therapy had a significant anabolic effect in CF patients as shown by increased growth velocity, SmC values, increased protein and decreased fat stores, and a positive or less negative net nitrogen retention in five of the patients.

Original languageEnglish (US)
Pages (from-to)90-95
Number of pages6
JournalPediatric Pulmonology
Volume22
Issue number2
DOIs
StatePublished - Aug 1 1996

Fingerprint

Anabolic Agents
Cystic Fibrosis
Growth Hormone
Human Growth Hormone
Nitrogen
Therapeutics
Insulin-Like Growth Factor I
Bone and Bones
Lung
Growth
Fats
Peak Expiratory Flow Rate
Weight Gain
Thyroid Gland

Keywords

  • Growth hormone treatment
  • cystic fibrosis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients. / Huseman, Carol A.; Colombo, John Louis; Brooks, Margaret A.; Smay, Jeanne R.; Greger, Nancy G.; Sammut, Paul Henry; Bier, Dennis M.

In: Pediatric Pulmonology, Vol. 22, No. 2, 01.08.1996, p. 90-95.

Research output: Contribution to journalArticle

Huseman, Carol A. ; Colombo, John Louis ; Brooks, Margaret A. ; Smay, Jeanne R. ; Greger, Nancy G. ; Sammut, Paul Henry ; Bier, Dennis M. / Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients. In: Pediatric Pulmonology. 1996 ; Vol. 22, No. 2. pp. 90-95.
@article{25ab65d03a3141579f318fb817e22acc,
title = "Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients",
abstract = "The purpose of this study was to determine whether GH treatment of cystic fibrosis (CF) patients can result in an anabolic effect, i.e., increased weight gain, improved growth rate, nitrogen retention, and improved pulmonary function. Nine prepubertal endocrinologically normal CF patients (3 girls, 6 boys; chronological age (CA) 5.5-9.8 years, and bone age (BA) 4.5- 9.0 years), received recombinant human growth hormone (rhGH) 0.3 mg/kg/week subcutaneously for a period of 12 months (N = 8) or 9 months (N = 1). Normal glucose tolerance was determined before treatment. Pulmonary function studies and anthropometric measurements were done every 3 months. Thyroid status, somatomedin C (SmC), BA, and routine chemistries were evaluated every 6 months. The pretreatment growth velocity averaged 5.7 ± 0.3 (SE) cm/year and significantly increased to 7.8 ± 0.4 (SE) cm/year during therapy, (P < 0.01). Standard deviation scores (SDS) for height significantly increased during rhGH therapy as compared with pretreatment, (P < 0.05). Weight of the patients during rhGH therapy did not significantly change during or after rhGH therapy. After therapy, all patients showed a significant increase in arm muscle area (AMA) and a significant decrement in arm fat area (AFA) (P < 0.01). Net nitrogen anabolism was negative in all subjects before therapy but became more positive in five patients during rhGH therapy. Three patients achieved positive nitrogen retention. SmC values significantly increased from a mean value of 0.62 ± 0.1 (SE) U/ml to 1.6 ± 0.6 (SE) U/ml after therapy. BA advanced 1.0 ± 0.1 SE per year after treatment. Of the seven patients able to perform adequate pulmonary function testing, improvement occurred in FVC, FEV(10 t), and PEFR in 5, 5, and 4 patients, respectively, but these changes did not reach statistical significance. We conclude that biosynthetic rhGH therapy had a significant anabolic effect in CF patients as shown by increased growth velocity, SmC values, increased protein and decreased fat stores, and a positive or less negative net nitrogen retention in five of the patients.",
keywords = "Growth hormone treatment, cystic fibrosis",
author = "Huseman, {Carol A.} and Colombo, {John Louis} and Brooks, {Margaret A.} and Smay, {Jeanne R.} and Greger, {Nancy G.} and Sammut, {Paul Henry} and Bier, {Dennis M.}",
year = "1996",
month = "8",
day = "1",
doi = "10.1002/(SICI)1099-0496(199608)22:2<90::AID-PPUL2>3.0.CO;2-N",
language = "English (US)",
volume = "22",
pages = "90--95",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients

AU - Huseman, Carol A.

AU - Colombo, John Louis

AU - Brooks, Margaret A.

AU - Smay, Jeanne R.

AU - Greger, Nancy G.

AU - Sammut, Paul Henry

AU - Bier, Dennis M.

PY - 1996/8/1

Y1 - 1996/8/1

N2 - The purpose of this study was to determine whether GH treatment of cystic fibrosis (CF) patients can result in an anabolic effect, i.e., increased weight gain, improved growth rate, nitrogen retention, and improved pulmonary function. Nine prepubertal endocrinologically normal CF patients (3 girls, 6 boys; chronological age (CA) 5.5-9.8 years, and bone age (BA) 4.5- 9.0 years), received recombinant human growth hormone (rhGH) 0.3 mg/kg/week subcutaneously for a period of 12 months (N = 8) or 9 months (N = 1). Normal glucose tolerance was determined before treatment. Pulmonary function studies and anthropometric measurements were done every 3 months. Thyroid status, somatomedin C (SmC), BA, and routine chemistries were evaluated every 6 months. The pretreatment growth velocity averaged 5.7 ± 0.3 (SE) cm/year and significantly increased to 7.8 ± 0.4 (SE) cm/year during therapy, (P < 0.01). Standard deviation scores (SDS) for height significantly increased during rhGH therapy as compared with pretreatment, (P < 0.05). Weight of the patients during rhGH therapy did not significantly change during or after rhGH therapy. After therapy, all patients showed a significant increase in arm muscle area (AMA) and a significant decrement in arm fat area (AFA) (P < 0.01). Net nitrogen anabolism was negative in all subjects before therapy but became more positive in five patients during rhGH therapy. Three patients achieved positive nitrogen retention. SmC values significantly increased from a mean value of 0.62 ± 0.1 (SE) U/ml to 1.6 ± 0.6 (SE) U/ml after therapy. BA advanced 1.0 ± 0.1 SE per year after treatment. Of the seven patients able to perform adequate pulmonary function testing, improvement occurred in FVC, FEV(10 t), and PEFR in 5, 5, and 4 patients, respectively, but these changes did not reach statistical significance. We conclude that biosynthetic rhGH therapy had a significant anabolic effect in CF patients as shown by increased growth velocity, SmC values, increased protein and decreased fat stores, and a positive or less negative net nitrogen retention in five of the patients.

AB - The purpose of this study was to determine whether GH treatment of cystic fibrosis (CF) patients can result in an anabolic effect, i.e., increased weight gain, improved growth rate, nitrogen retention, and improved pulmonary function. Nine prepubertal endocrinologically normal CF patients (3 girls, 6 boys; chronological age (CA) 5.5-9.8 years, and bone age (BA) 4.5- 9.0 years), received recombinant human growth hormone (rhGH) 0.3 mg/kg/week subcutaneously for a period of 12 months (N = 8) or 9 months (N = 1). Normal glucose tolerance was determined before treatment. Pulmonary function studies and anthropometric measurements were done every 3 months. Thyroid status, somatomedin C (SmC), BA, and routine chemistries were evaluated every 6 months. The pretreatment growth velocity averaged 5.7 ± 0.3 (SE) cm/year and significantly increased to 7.8 ± 0.4 (SE) cm/year during therapy, (P < 0.01). Standard deviation scores (SDS) for height significantly increased during rhGH therapy as compared with pretreatment, (P < 0.05). Weight of the patients during rhGH therapy did not significantly change during or after rhGH therapy. After therapy, all patients showed a significant increase in arm muscle area (AMA) and a significant decrement in arm fat area (AFA) (P < 0.01). Net nitrogen anabolism was negative in all subjects before therapy but became more positive in five patients during rhGH therapy. Three patients achieved positive nitrogen retention. SmC values significantly increased from a mean value of 0.62 ± 0.1 (SE) U/ml to 1.6 ± 0.6 (SE) U/ml after therapy. BA advanced 1.0 ± 0.1 SE per year after treatment. Of the seven patients able to perform adequate pulmonary function testing, improvement occurred in FVC, FEV(10 t), and PEFR in 5, 5, and 4 patients, respectively, but these changes did not reach statistical significance. We conclude that biosynthetic rhGH therapy had a significant anabolic effect in CF patients as shown by increased growth velocity, SmC values, increased protein and decreased fat stores, and a positive or less negative net nitrogen retention in five of the patients.

KW - Growth hormone treatment

KW - cystic fibrosis

UR - http://www.scopus.com/inward/record.url?scp=0029846931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029846931&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1099-0496(199608)22:2<90::AID-PPUL2>3.0.CO;2-N

DO - 10.1002/(SICI)1099-0496(199608)22:2<90::AID-PPUL2>3.0.CO;2-N

M3 - Article

C2 - 8875581

AN - SCOPUS:0029846931

VL - 22

SP - 90

EP - 95

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 2

ER -